DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
About
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
The DoW Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award supports researchers and organizations pursuing innovative, high-risk, high-gain ideas in ALS drug and therapy discovery. This grant is designed for scientists and research teams with novel hypotheses that could advance therapeutic investigation, even without extensive preliminary data. The award is ideal for researchers ready to generate foundational evidence that could lead to future clinical applications. If you're working on breakthrough approaches to ALS treatment or drug development, this program encourages hypothesis-driven research that demonstrates strong scientific methodology and potential for significant impact. The Therapeutic Idea Award recognizes that transformative discoveries often begin with bold concepts backed by rigorous science. Applicants should focus on the strength of their scientific approach and the innovation potential of their proposed work. This is an excellent opportunity for researchers seeking federal funding to pursue cutting-edge ALS research with the flexibility to develop preliminary data that will support larger, follow-on investigations. The program prioritizes creative thinking and scientific merit, making it accessible to research teams at various stages of development.
Funding Facts
● Applications openDeadline
September 30, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle—see official program announcement
Deadline
2026-09-30
Grant Type
federal
Application Cycle
Annual—FY2026 deadline September 30, 2026
Best For
Research institutions and scientists pursuing innovative ALS drug and therapy discovery with novel, hypothesis-driven approaches
Frequently Asked Questions
Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award?
Specific eligibility criteria have not been provided in available information. Typically, Department of Defense research awards support academic institutions, research organizations, and qualified research entities. For definitive eligibility requirements, including institutional qualifications, citizenship status, and other specific criteria, please visit the official DoD ALSRP program website or contact the program administrator directly.
How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award provide?
Funding amounts are not specified in the available information. Award amounts may vary by fiscal year and program priorities. Visit the official DoD ALSRP website for FY2026 funding information, including budget limits and funding ranges for the Therapeutic Idea Award.
How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award?
Applications are typically submitted through the DoD's grants management system during designated submission periods. The deadline for FY2026 submissions is September 30, 2026. Applicants should review the official Funding Opportunity Announcement (FOA) on the DoD ALSRP website for detailed instructions, required forms, proposal format specifications, and submission procedures. Early review of guidelines is recommended to ensure compliance.
What can DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award funding be used for?
This award supports hypothesis-driven research aimed at ALS drug discovery and therapy development. Funding is intended to support innovative, high-risk research concepts that generate preliminary data for future therapeutic investigation. Research should focus on novel approaches with strong potential for impact. For specific allowable expenses and cost-sharing requirements, refer to the official program announcement and DoD research regulations.
Last updated: July 5, 2026